TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

EicOsis has Initiated a Phase 1B Clinical Trial For EC5026

Wednesday, January 31, 2024

EicOsis Human Health, a pharmaceutical company specializing in non-narcotic oral analgesics targeting the soluble epoxide hydrolase (sEH) enzyme, has recently announced the initiation of its Phase 1b multiple-ascending dose clinical trial for the drug candidate EC5026.

The trial, designed as a double-blind, placebo-controlled study, aims to assess the safety and pharmacokinetics of daily doses of EC5026 over a seven-day period. Preliminary findings suggest no observable changes in vital signs, behavior, or adverse effects in the subjects.

EC5026, a potent sEH enzyme inhibitor, plays a critical role in modulating the metabolism of signaling lipids involved in inflammation and stress responses. By preventing the breakdown of natural analgesic and anti-inflammatory fatty acids, EC5026 represents a potential non-opioid solution for moderate to severe pain. Preclinical studies have demonstrated no sedation, adverse behavioral effects, or signs of addiction.

The discovery of the enzyme inhibitor can be credited to Bruce Hammock, a UC Davis distinguished professor and the founder of EicOsis, who highlighted its significance in regulating inflammation, pain, fibrosis, depression, and neuroinflammation.

Dr. William K Schmidt, the VP of Clinical Development at EicOsis, expressed optimism about the Phase 1b study, emphasizing the positive safety profile observed in previous trials. EicOsis plans to initiate a pain patient study in April 2024, targeting individuals with spinal cord injuries experiencing inadequate pain relief with current non-opioid medications.

The FDA granted Fast Track status to EC5026 due to the pressing need for safe and effective non-opioid analgesics, addressing a significant unmet medical need. Various initiatives from the National Institutes of Health (NIH) have supported EC5026's progression into clinical trials.

Cindy McReynolds, the CEO of EicOsis, views the Phase 1b program as a crucial milestone, anticipating the evaluation of efficacy in subsequent patient studies. EicOsis is dedicated to advancing safe and effective treatments for serious diseases and providing alternatives for pain management.

The name EicOsis, derived from eicosanoids, symbolizes the importance of the epoxide group in the arachidonate cascade—the focal point of the sEH enzyme. Chronic pain affects around 20% of Americans, with an annual economic toll of $560 billion. EicOsis aims to contribute to addressing this public health concern.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit